US › Healthcare

Mereo BioPharma Group PLC ADR (MREO)

US · Healthcare · Biotechnology

$0.32+2.09%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-6.7M
Profit YoY
+47.9%
EPS
$-0.01
EPS estimate
$-0.01

EPS came in at -0.01 against a street estimate of -0.01 — a beat of 43.4%.

Key statistics

Market cap
$54.7M
Forward P/E
0.0
P/B
1.62
Book value
$0.21
EPS (TTM)
$-0.20
52-week high
$2.37
52-week low
$0.20
50-day MA
$0.31
200-day MA
$0.78
Beta
0.29

Analyst view

Analysts rate Mereo BioPharma Group PLC ADR a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $1.98.

Shareholding

Insiders
0.75%
Institutions
47.89%

Largest institutional holders

FundStake
Rubric Capital Management LP9.59%
EcoR1 Capital, LLC8.38%
683 Capital Management LLC7.52%
Bank of America Corp5.13%
Defilade Capital Management, L.P.4.74%
Newtyn Management LLC4.43%
Millennium Management LLC2.23%
Tejara Capital Ltd1.28%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Mereo BioPharma Group PLC ADR — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.